Swedish rare immunology specialist Hansa Biopharma AB has reported positive topline results from a European post-authorisation efficacy study of Idefirix, strengthening its case to convert the kidney transplant drug’s conditional EU approval into full marketing authorisation.
SERB Pharmaceuticals has agreed to pay Hansa Biopharma €110 million upfront for European rights to a conditionally approved kidney transplant drug.
As Amgen’s competing therapy has come under growing regulatory scrutiny, an opportunity has emerged for InflaRx N.V. to position its own oral C5aR inhibitor in the market. The Jena-based biotech company is now moving quickly to capitalise on that opening: InflaRx is refocusing its pipeline on severe renal diseases while simultaneously advancing a US$150m capital raise intended to fund development through key clinical milestones.
The FDA has approved Novo Nordisk’s blockbuster drug Ozempic (semaglutide) for patients with chronic kidney disease who also have type 2 diabetes.
Purespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B round. Led by Sofinnova Partners, this funding also drew support from Gilde Healthcare, Forbion, British Patient Capital, and Syncona Limited.
InflaRx 
Bild von freepik
Image by freepik